Arrowhead Pharmaceuticals, Inc. (ARWR): Shareholders' Equity
$503.42M
As of 2025-09-30
$466.04M
As of 2026-06-30
+6.4%
3-year compound annual growth
+1.7%
5-year compound annual growth
+16.5%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $503.42M | +163.5% | 2025-11-25, Balance as of period end |
| 2024-09-30 | $191.06M | -33.5% | 2025-11-25, Balance as of period end |
| 2023-09-30 | $287.16M | -31.4% | 2025-11-25, Balance as of period end |
| 2022-09-30 | $418.34M | +2.3% | 2024-11-26, Balance as of period end |
| 2021-09-30 | $408.82M | -11.5% | 2023-11-29, Balance as of period end |
| 2020-09-30 | $461.78M | +89.2% | 2022-11-28, Balance as of period end |
| 2019-09-30 | $244.04M | +156.2% | 2021-11-22, Balance as of period end |
| 2018-09-30 | $95.24M | +17.8% | 2020-11-23, Balance as of period end |
| 2017-09-30 | $80.87M | -14.9% | 2019-11-25, Balance as of period end |
| 2016-09-30 | $95.02M | -13.3% | 2018-12-11, Balance as of period end |
| 2015-09-30 | $109.62M | -34.0% | 2017-12-12, Balance as of period end |
| 2014-09-30 | $165.99M | +545.0% | 2016-12-14, Balance as of period end |
| 2013-09-30 | $25.73M | +192.1% | 2015-12-14, Balance as of period end |
| 2012-09-30 | $8.81M | -29.9% | 2014-11-25, Balance as of period end |
| 2011-09-30 | $12.56M | +55.5% | 2013-12-18, Balance as of period end |
| 2010-09-30 | $8.08M | +66.3% | 2013-12-18, Balance as of period end |
| 2009-09-30 | $4.86M | -60.5% | 2013-12-18, Balance as of period end |
| 2008-09-30 | $12.30M | -53.5% | 2013-12-18, Balance as of period end |
| 2007-09-30 | $26.46M | -16.3% | 2013-12-18, Balance as of period end |
| 2006-09-30 | $31.61M | +12.8% | 2013-12-18, Balance as of period end |
| 2005-09-30 | $28.03M | +149.6% | 2013-12-18, Balance as of period end |
| 2004-09-30 | $11.23M | +690.8% | 2013-12-18, Balance as of period end |
| 2003-09-30 | $1.42M | n/a | 2013-12-18, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $503.42M | +163.5% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $870.22M | +32.0% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $301.68M | +31.8% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $540.72M | +33.9% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $647.80M | -4.7% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $522.60M | +8.2% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $489.09M | -16.9% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $693.11M | -11.0% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $788.80M | +7.7% |
Compare ARWR, HRMY, COLL, ANIP side by side · Screen every company in Pharmaceutical Preparations ↗